New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
05:55 EDTABT, ABT, BSX, BSX, JNJ, JNJ, MDT, MDT, STJ, STJ, EW, EW, ATRC, ATRC, HT, HTLeerink's medical supplies and devices analyst holds a luncheon
Medical Supplies & Devices Analyst Antalffy holds a luncheon meeting where the focus is on current market paradigms and future growth drivers in interventional cardiology at the Variety Club Research Center at the University of Minnesota, Minneapolis on March 20 at 11 am.
News For ABT;BSX;JNJ;MDT;STJ;EW;ATRC;HT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 20, 2015
05:29 EDTSTJSt. Jude Medical announces preliminary results from ILUMIEN I and ILUMIEN II
St. Jude Medical announced preliminary results from the ILUMIEN I trial and final results from the ILUMIEN II clinical study. Taken together, the findings from both studies show that with resolution up to 10 times higher than intravascular ultrasound, optical coherence tomography imaging can help improve stent selection and deployment, better support clinical decision-making and improve patient outcomes. In the prospective study to date examining OCT’s impact on clinical decisions and their associated outcomes, ILUMIEN I assessed 418 patients suffering stable or unstable angina or non-ST segment elevation myocardial infarction. The study’s 12-month data shows: OCT guidance conducted either pre- or post-PCI altered physician decision-making in 65% of patients; Pre-PCI OCT altered treatment planning in 55% of patients and led to changes in decisions related to stent length and diameter; OCT imaging was associated with a reduction of in-hospital MI when used pre- and post-PCI to change the procedural strategy. The ILUMIEN II study was designed to determine whether OCT guidance results in a comparable degree of stent expansion as IVUS imaging. After an analysis of OCT-guided stenting or IVUS-guided stenting in 940 patients from the ILUMIEN I and ADAPT-DES studies, the degree of stent expansion was found to be comparable between OCT and IVUS imaging. The study’s data shows OCT and IVUS guidance were also associated with comparable rates of major stent malapposition, tissue protrusion and stent edge dissection.
May 19, 2015
16:10 EDTJNJAchillion enters into collaboration for HCV with Janssen
Achillion (ACHN) announced that it has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to develop and commercialize one or more of Achillion's lead hepatitis C virus, or HCV, assets which include ACH-3102, ACH-3422, and sovaprevir. Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the collaboration and all subsequent costs related to commercialization of the HCV assets. A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in Phase 2 clinical studies that has been granted Fast Track designation by the U.S. Food and Drug Administration, in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration. Additionally, in an equity transaction separate to the exclusive license and collaboration arrangement, Johnson & Johnson Innovation – JJDC, Inc. will invest $225M in Achillion and, in return, receive approximately 18.4M newly issued, unregistered shares of Achillion at a price of $12.25 per share. The transactions, including the equity sale, are subject to customary closing conditions, including termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act. Transitional clinical development and technology transfer activities under the collaboration are expected to take place over the next several months.
09:21 EDTEWEdwards Lifesciences voluntarily pauses enrollment for Fortis clinical program
Subscribe for More Information
08:48 EDTEWEdwards Lifesciences reports positive results from treatment with SAPIEN 3
Subscribe for More Information
08:40 EDTMDTMedtronic sees FY15 revenue $20.3B, may not compare to consensus $28.15B
Subscribe for More Information
08:40 EDTMDTMedtronic sees Q4 adjusted EPS at upper half of $1.08-1.13, consensus $1.10
Subscribe for More Information
08:05 EDTSTJSt. Jude Medical announces Canadian launch of Prodigy Chronic Pain System
Subscribe for More Information
08:02 EDTABTAbbott announces CE Mark for new advancement of Absorb stent system
Subscribe for More Information
07:54 EDTBSXBoston Scientific reports positive data from EVOLVE trial
Subscribe for More Information
May 18, 2015
11:23 EDTABTFitch downgrades Abbott's L-T IDR to A; outlook revised to stable
Subscribe for More Information
09:27 EDTMDTMedtronic announces study results showing CRT system optimizes treatment
Subscribe for More Information
May 15, 2015
14:20 EDTSTJSt. Jude Medical reports positive results from CardioMEMS HF System
Subscribe for More Information
14:01 EDTSTJSt. Jude Medical reports positive results from Allure Quadra CRT-P System
St. Jude Medical announced the presentation of important data supporting the first and only quadripolar cardiac resynchronization therapy pacemaker system in the U.S., during the Heart Rhythm Society's 36th annual scientific sessions. The Allure Quadra CRT-P system, with the Quartet Quadripolar LV Lead is associated with a 63% reduction in the need to replace the lead or deactivate CRT following implant. Quadripolar LV pacing using SJM quadripolar CRT-Ds or CRT-Ps and an SJM quadripolar lead provides physicians with multiple pacing options to avoid phrenic nerve stimulation and allow for optimal treatment delivery without the need to replace or deactivate the therapy. An analysis evaluating more than 3,000 patients implanted with a CRT-P (1,325 with a quadripolar lead vs. 1,930 with a bipolar lead) looked at whether the known decreased need to replace or deactivate LV leads associated with SJM quadripolar CRT-Ds and the Quartet LV lead also extends to St. Jude Medical quadripolar CRT-Ps. The retrospective data analysis was presented in a session titled Quadripolar Leads are Associated with Fewer LV Lead Replacements and Deactivations in CRT-P Patients by Dr. Mintu P. Turakhia, who led the investigation. The data show that patients with the Quartet LV lead were 63% less likely to undergo lead replacement or deactivation of CRT compared to the patients with bipolar leads.
13:33 EDTMDTMedtronic: TYRX antibacterial envelope reduces cardiac device infection rates
Subscribe for More Information
10:29 EDTBSXAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTBSXAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:45 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
08:41 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
08:12 EDTMDTMedtronic Micra TPS meets initial safety, performance measures
Subscribe for More Information
07:35 EDTJNJMedivation price target raised to $148 from $128 at Leerink
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use